Memgen

Memgen is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and treatments for viral diseases, including COVID-19. The company's proprietary CD40L transgene, MEM40, underpins its therapeutic pipeline. Memgen's lead product, MEM-288, is an oncolytic virus developed in partnership with Moffitt Cancer Center, designed to selectively target cancer cells while enhancing the immune response through the expression of MEM40 and interferon beta. This therapy aims to induce a robust systemic anti-tumor immune response following intra-tumoral administration across various tumors. Memgen plans to initiate clinical trials for MEM-288 in advanced cancer cases. Additionally, the company is advancing its COVID-19 vaccine candidate, MemVax, which acts as an adjuvant to enhance immune responses when combined with existing COVID-19 vaccines. With over 100,000 doses prepared for clinical testing and an active filing with the US FDA, Memgen is poised to collaborate with other vaccine developers to assess MemVax's efficacy in clinical trials.